Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

Shares of solid tumor concern Zymeworks Inc. have barely budged since the company obtained its first approval. Click here to read why ZYME stock is a Hold.

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

The Micro Immune Response On chip (MIRO) allows tumours and their environment to be replicated in order to understand their ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

The FDA made strides in R/R T-cell lymphoma and breast cancer. An AI tool aids pathologists and other positive updates in gastric cancer and NSCLC.

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Giving patients with a common form of breast cancer an immunotherapy drug before surgery appears to boost outcomes, a n ...

Paul Nghiem, MD, PhD, and the Nghiem Lab have championed innovations in MCC treatment, delivering new treatment options, ...

The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.